Completion of ongoing outcome clinical trials will provide information on both the expected clinical benefit and the safety of inclisiran administered for longer.doi:10.1007/s11883-022-01056-0Angela.PirilloCenter for the Study of Atherosclerosis, E. Bassini Hospital, Cinisello Balsamo, Milan, Italy....
therapeutics possible. Nearly 15 years of work by Alnylam delivered the world’s first approved RNAi therapeutic—ONPATTRO® (patisiran)—in 2018 and, subsequently, GIVLAARI® (givosiran), OXLUMO® (lumasiran), Leqvio® (inclisiran)*, AMVUTTRA® (vutrisiran) and Qfitlia™ (fitus...
Ray KK et al (2017) Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 376(15):1430–1440 Article CAS PubMed Google Scholar Drugs.com. Alnylam announces FDA acceptance of New Drug Application (NDA) and priority review status for patisiran, an ...
Inclisiran is a small interfering RNA that produces sustained interference with the expression of hepatocyte-specific PCSK9; the drug showed LDL-C reductions of approximately 50% at day 180 after administration of two 300-mg doses on days 1 and 90, as well as reductions in Lp(a) of approx...